Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM). Tubulin inhibitor 17 exhibits anticancer activities as well as induces cell apoptosis[1].

Tubulin inhibitor 17 (Compound 3b) (0-10 μM, 0-72 h) shows antiproliferative activities against cancer cells and inhibits colony formation of HepG-2 cells [1]. Tubulin inhibitor 17 (0-2.5 μM) concentration dependently inhibits tubulin polymerization[1]. Tubulin inhibitor 17 (0-1 μM, 12 h) dose-dependently induces the collapse of the microtubule networks[1]. Tubulin inhibitor 17 (0-5 μM, 24 h) induces cell cycle arrest at G2/M phase as well as inhibits cell migration of HepG-2 cells [1]. Tubulin inhibitor 17 (0-5 μM, 48 h) induces apoptosis in HepG-2 cells [1]. Cell Proliferation Assay [1] Cell Line: B16-F10, HepG-2, Hela and MCF-7 Concentration: 0, 0.5, 2.5, 5.0, 7.5 and 10 μM Incubation Time: 48 h for IC 50 measurement, 0-72 h for cell viability Result: Demonstrated antiproliferative activities with IC 50 values of 0.563 ± 0.099, 0.261 ± 0.025, 2.047 ± 0.168 and 0.609 ± 0.062 μM against B16-F10, HepG-2, Hela and MCF-7 cells, respectively. Inhibited the cell viability in a concentration- and time-dependent manner. Cell Cycle Analysis [1] Cell Line: HepG-2 Concentration: 0.5, 1.0 and 5.0 μM Incubation Time: 24 h Result: Dose-dependent induction of cell cycle arrest in G2/M phase. Apoptosis Analysis [1] Cell Line: HepG-2 Concentration: 0.5, 1.0 and 5.0 μM Incubation Time: 48 h Result: The overall proportion of apoptotic cells was significantly increased compared to the control.